Soria, J-C <br/><br/>
SELECT-2: a phase II, double-blind, randomized, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment of patients with advanced or metastatic non-small-cell lung cancer.  [electronic resource] 

 -  Annals of oncology : official journal of the European Society for Medical Oncology  Dec 2017 
 - 3028-3036 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1569-8041 
<br/><br/><label>Standard No.: </label>10.1093/annonc/mdx628  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Benzimidazoles--administration & dosage<br/>Carcinoma, Non-Small-Cell Lung--drug therapy<br/>Disease-Free Survival<br/>Docetaxel<br/>Double-Blind Method<br/>Female<br/>Humans<br/>Lung Neoplasms--drug therapy<br/>Male<br/>Middle Aged<br/>Neoplasm Metastasis<br/>Proto-Oncogene Proteins p21(ras)--genetics<br/>Taxoids--administration & dosage